What they are doing is pretty complex, but basically they use deep sequencing of circulating tumor DNA looking for known mutations using hybrid targeting. Potentially could be used as a screening test or to follow mutations under treatment.
Probably a few years out yet, but very important in the long run. Getting tumor material for a lung biopsy is sometimes quite hard and can have significant morbidity.